DCyFIR: a high-throughput CRISPR platform for multiplexed G protein-coupled receptor profiling and ligand discovery
Author(s) -
Nicholas J. Kapolka,
Geoffrey J. Taghon,
Jacob B. Rowe,
William M. Morgan,
J. F. Enten,
Nevin A. Lambert,
Daniel G. Isom
Publication year - 2020
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2000430117
Subject(s) - druggability , g protein coupled receptor , computational biology , drug discovery , profiling (computer programming) , receptor , crispr , in silico , biology , chemical biology , high throughput screening , bioinformatics , computer science , biochemistry , gene , operating system
Significance G protein-coupled receptors (GPCRs) are the largest class of membrane receptors in humans. As such, GPCR signaling is central to human biology and medicine. While more than 30% of approved drugs target roughly 150 GPCRs, most receptors lack well-defined endogenous ligands and are currently not druggable. To address this challenge, we created DCyFIR, a GPCR screening platform for ligand and drug discovery. This technology enables the cost-effective profiling of ligands and drug compounds against mixtures of hundreds of GPCR-barcoded cell strains in a single experiment. Because ligands are tested against many receptors simultaneously, DCyFIR profiling will eventually enable the physical screening of huge numbers of compounds, bringing wet-laboratory experimental throughput a step closer to what is done in silico.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom